|
|
Legal status
Patent expired
| (51) | INT.CL. | A61K 39/12 | (2006.01) |
| (11) | Number of the document | 1758609 |
| (13) | Kind of document | T |
| (96) | European patent application number | 05757953.4 |
| Date of filing the European patent application | 2005-06-14 | |
| (97) | Date of publication of the European application | 2007-03-07 |
| (45) | Date of publication and mention of the grant of the patent | 2012-10-03 |
| (46) | Date of publication of the claims translation | 2012-12-27 |
| (86) | Number | PCT/EP2005/006461 |
| Date | 2005-06-14 |
| (87) | Number | WO 2005/123125 |
| Date | 2005-12-29 |
| (30) | Number | Date | Country code |
| 0413510 | 2004-06-16 | GB | |
| 114301 | 2005-04-26 | US |
| (72) |
DEBRUS, Serge, BE
MARTIN, Marie-Therese, BE
STEPHEN, Robert John, GB
STEPHENNE, Jean, BE
WETTENDORFF, Martine, Anne, Cécile, BE
|
| (73) |
GlaxoSmithKline Biologicals SA,
Rue de l`Institut 89, 1330 Rixensart,
BE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Vakcina prieš HPV16 ir HPV18 ir mažiausiai vieną kitą HVP tipą, parinktą iš HVP 31, 45 arba 52 |
| VACCINE AGAINST HPV16 AND HPV18 AND AT LEAST ANOTHER HPV TYPE SELECTED FROM HPV 31, 45 OR 52 |
| Payment date | Validity (years) | Amount | |
| 2024-05-21 | 347.00 EUR |